Citations

Clear

196 citation(s) found for "Schultz, M".

Longitudinal Detection of Circulating Tumor DNA in Children with Pleuropulmonary Blastoma: A Report from the International PPB/DICER1 Registry
Schultz, Kris Ann P , Field, Amanda L , Mallinger, Paige H R , Xu, Chenyu , Deonovic, Benjamin , Nelson, Alexander T , Watson, Dave , Hagedorn, Kelly , Olson, Damon R , Kamihara, Junne , Chen, Kenneth S , Mitchell, Sarah G , Wilson, David B , Amend, Christina E , Mize, William , Su, Yan , Duan, Chao , Yue, Zhixia , Gao, Chao , Klega, Kelly S. , Dehner, Louis P , Messinger, Yoav H , Crompton, Brian D , Harris, Anne K , Hill, Dana Ashley

Mayo Clinic

Clinical Cancer Research | November 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/1078-0432.ccr-26-1981 | PMID 43043066 Get It

Abstract Purpose: Pleuropulmonary blastoma (PPB) is the most common lung cancer of early childhood. Nearly all PPBs have biallelic DICER1 variants: a loss-of-function allele (often germline) and a second RNase IIIb domain "hotspot" substitution. Except in somatic mosaicism, these hotspots are tumor-specific and ideal liquid biopsy targets. Experimental Design: For individuals with PPB enrolled in the International PPB/DICER1 Registry, blood samples were collected at timepoints coordinated with clinical venous access. Tumor sequencing identified each patient's RNase IIIb hotspot, enabling personalized droplet digital PCR assays to detect that variant in circulating tumor DNA (ctDNA). Results: We analyzed 482 samples from 20 type I and 53 type II/III PPB patients. Among 13 pre-operative type II/III patients sampled pretreatment, 11 (85%) had detectable ctDNA, with tumor size moderately correlated with ctDNA burden (Spearman's ρ=0.574, p=0.051). In contrast, among 8 patients sampled after resection but before chemotherapy, none had detectable ctDNA (p<0.001 vs. unresected). After chemotherapy initiation, ctDNA levels spiked within 1–2 days before rapidly declining. During post-event surveillance, ctDNA was detectable a median of 5.3 weeks before clinical progression (21.7 weeks for negative samples; p=0.001). In type I PPB, DICER1 variants were detectable only in patients with somatic mosaicism. Conclusions: In type II/III PPB, ctDNA correlates with tumor size and resection status. The transient rise and fall in ctDNA following initiation of chemotherapy suggests that ctDNA could serve as a real-time in vivo assay of tumor responsiveness, and these findings support further investigation as a pharmacodynamic biomarker for disease response and recurrence detection.
Time-of-Day of Initial Immune Checkpoint Inhibitor Administration and Its Impact on Outcomes in Metastatic Non–Small Cell Lung Cancer
Schultz, Sydney , Mohr, Riley , Cole, Kristin , Knott, Amanda, Amundson, Briana K., King, Elizabeth B , Hardler, Michael , Chittavong, Vayou, Campian, Jian , Dimou, Anastasios

Mayo Clinic

JCO Oncology Practice | November 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-26-00491 | PMID 42981555 Get It

Purpose Immune checkpoint inhibitors (ICIs) are integral to first-line treatment of metastatic non–small cell lung cancer (NSCLC). Circadian biology may influence antitumor immunity, raising the hypothesis that time-of-day of ICI administration could affect outcomes. We evaluated the association between initial and cumulative ICI administration time-of-day and clinical outcomes in metastatic NSCLC. Materials and Methods We conducted a retrospective cohort study of 778 patients with metastatic NSCLC treated with first-line ICI-containing therapy across Mayo Clinic sites between January 2021 and March 2024. Patients were stratified by time-of-day of first ICI administration: early (0700-1200) versus late (1201-2400). Primary end points were overall survival (OS) and progression-free survival (PFS); the secondary end point was immune-related toxicity. Multivariable Cox proportional hazards models adjusted for clinically relevant covariates. Exploratory analyses evaluated cumulative infusion time-of-day and alternative administration-time thresholds using spline and cut-point analyses. Results Of 778 patients, 277 received early and 501 received late initial ICI administration. Median OS was 1.33 versus 1.48 versus years and median PFS was 0.65 versus 0.67 years in the late and early groups, respectively. Time-of-day of initial ICI administration was not associated with OS (HR, 1.01 [95% CI, 0.85 to 1.20]) or PFS (HR, 1.03 [95% CI, 0.88 to 1.21]). Findings were unchanged after multivariable adjustment. Immune-related toxicity occurred in 26.9% and 24.2% of patients in the late and early groups, respectively ( P = .40). Cumulative infusion time-of-day was not associated with OS or PFS, and spline analyses identified no significant administration-time threshold associated with outcomes. Conclusion In this large real-world cohort of patients with metastatic NSCLC, neither initial nor cumulative ICI administration time-of-day was associated with survival or immune-related toxicity. Prospective studies incorporating chronotype and circadian biomarkers are warranted to further define the role of chronotherapy in immuno-oncology.
Clostridium ramosum Bacteremia: Clinical Significance and Outcomes in a Multicenter Retrospective Cohort
Gavrancic, Tatjana , Stoddard, Kassandra, Tahir, Muhammad Waqas , Gorasevic, Marko, Cortes, Melissa, Prada, Libardo Rueda , Baptista, Aleksandra Murawska , Pagán, Ricardo J, Schultz, Carrie S., Elwasilla, Sammer M, Schuetz, Audrey N, Dumic, Igor , Pagán, Ricardo J. , Elwasila, Sammer M , Schuetz, Audrey N.

Mayo Clinic

No container title available | September 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10554696/v1 Get It

Abstract Background: Clostridium ramosum ( C. ramosum ) is an anaerobic gram-positive bacillus of the human intestine and a rare cause of bacteremia. This retrospective cohort study evaluated clinical characteristics and outcomes of a multicenter cohort of adults with C. ramosum bacteremia. Methods: This multicenter retrospective cohort included adults (≥ 18 years) with true C. ramosum bacteremia at Mayo Clinic hospitals in Arizona, Florida, Minnesota, and Wisconsin from September 1, 2012, through December 31, 2025. Data were collected through search for C. ramosum in microbiological culture records. Clinical characteristics assessed included immune status, source of bacteremia, presence of sepsis, neutropenic fever, monomicrobial vs. polymicrobial bacteremia, antimicrobial resistance patterns, antimicrobial therapy, length of stay and 30-day all cause mortality. Exploratory odds ratios (ORs) with 95% confidence intervals (CIs) were reported. Results: Among 90 patients with a positive C. ramosum blood culture, 17 were classified as contaminants and 73 comprised the study cohort. Median age was 66.0 years (IQR, 56.0–75.0); 44 (60.3%) were male and 33 (45.2%) were immunocompromised (including 26 with active malignancy, while the remaining 7 were received biologic immunosuppression). The most common infection sources were gastrointestinal (32/73, 43.8%) and central line-related (8/73, 11%). At presentation, 50.7% of patients met criteria for sepsis and 15/73 (20.5%), were in septic shock. Of 73 isolates tested, 31/73 (44.3%) were clindamycin resistant and 9/73 (12.9%) tested intermediate. Anaerobic-active antimicrobial therapy was received by 53/73 (72.6%). Thirty-day mortality was 11/73 (15.1%). Mortality was 30.0% (6/20) with therapy without reliable anaerobic activity and 9.4% (5/53) with anaerobic-active antimicrobial therapy (OR, 4.02; 95% CI, 0.88–19.46; P = 0.060). The median hospital LOS was 8.0 days. Among 30-day survivors, anaerobic active antimicrobial therapy was associated with a shorter median LOS compared to therapy without reliable anaerobic activity (8.5 vs. 12.0 days). Immunocompromised patients had higher odds of monomicrobial C. ramosum bacteremia than immunocompetent patients (OR 3.16, 95% CI 1.19–8.39; p = 0.03). Patients with polymicrobial bacteremia had higher odds of sepsis (OR, 3.89; 95% CI, 1.43–10.55; P = 0.008) and septic shock (OR, 5.66; 95% CI, 1.17–27.36; P = 0.020). Patients with malignancy or neutropenia demonstrated significantly lower odds of presenting in septic shock (p = 0.018; p = 0.029 retrospectively). Microbiological clearance was achieved in 91.3% (42/46) of evaluable cases. Conclusions: This largest reported cohort defines the clinical and microbiological profile of C. ramosum bacteremia. Frequent clindamycin nonsusceptibility is clinically actionable. Several clinical associations found on univariable analysis should be further investigated in larger studies.
Comparative Dosing of Bevacizumab for Radiation Necrosis: Impact of Tumor Type on Edema Response
Schultz, Sydney E., Labib, Milisia, Breit, Jeff, Barreto, Jasón, Mead‐Harvey, Carolyn , Behairy, Mohamad, Nurioglu, Aylin, White, Jessica, Valerius, Allison , Taraba, Jodi L. , Soefje, Scott, Hoefs, Gena, Caron, Samantha, Ruff, Deborah, Uhm, Joon, Lachance, Daniel, Kizilbash, Dr Sani, Campian, Jian, Geyer, Susan, Neth, Bryan, Sener, Ugur, Schultz, Sydney , Barreto, Jason N. , Behair, Mohamad, White, Jessica B. , Karbhari, Nishika , Taraba, Jodi L , Soefje, Scott A. , Hoefs, Gena E, Caron, Samantha, Ruff, Michael W. , Uhm, Joon H. , Lachance, Daniel Honore , Kizilbash, Sani H. , Campian, Jian , Geyer, Susan M. , Neth, Bryan J. , Sener, Uğur

Mayo Clinic

No container title available | September 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10795946/v1 Get It

Abstract Purpose Bevacizumab is an effective treatment for radiation necrosis; dose dependent radiographic and edema response data are lacking. Methods Multicenter, retrospective cohort study of adult patients with primary central nervous system tumors or brain metastases who received bevacizumab for radiation necrosis between June 2021 and July 2024. Patients were grouped by bevacizumab dose (7.5 mg/kg vs 10 mg/kg administered every three weeks). Primary outcome was edema response, assessed by a blinded neuro-oncologist. Secondary outcomes included contrast enhancing disease response, clinical response, adverse events, treatment discontinuation, and re-dosing for recurrent radiation necrosis. Analyses were performed with and without adjustment for tumor type. Results 104 patients were included (7.5 mg/kg, n = 53; 10 mg/kg, n = 51). Edema response differed between dosing groups in unadjusted analyses (p = 0.032), favoring the 7.5 mg/kg cohort; however, this association was attenuated after adjustment for tumor type. Contrast enhancing disease response did not differ between groups in either unadjusted or adjusted analyses (p = 0.43). Clinical response was higher in the 7.5 mg/kg group (65.2% vs 37.8%, p = 0.013). Tumor type differed significantly between cohorts (p < 0.001), with more primary CNS tumors in the 10 mg/kg group. Rates of adverse events, treatment discontinuation, and re-dosing were similar. Conclusions While lower-dose bevacizumab was associated with greater edema reduction in unadjusted analyses, this effect was attenuated after accounting for tumor type. Importantly, 7.5 mg/kg dosing appeared sufficient for achieving edema control and contrast enhancing disease response. These findings support an individualized approach to bevacizumab dosing in radiation necrosis and highlight the need for prospective, tumor-stratified studies.
Improving First-Attempt Success Rate During Neonatal Intubation in a Tertiary NICU
Kaczor, Mark , Wilhelm, Jayden, Bosley, Christopher, Schultz, Tammy, Schram, Laura, Gallup, Maria Cristina , Stetson, Raymond C. , Kaczor, Mark W., Brumbaugh, Jane E. , Wilhelm, Jayden M, Bosley, Christopher, Schultz, Tammy, Schram, Laura

Mayo Clinic

Pediatrics | August 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1542/peds.2025-074216 | PMID 42624503 Get It

BACKGROUND AND OBJECTIVES Neonatal tracheal intubation is a high-risk procedure, and multiple attempts are associated with adverse events. At our tertiary neonatal intensive care unit, the baseline first-attempt success rate was 45%, which we aimed to increase to over 55% through a quality improvement (QI) initiative. METHODS A multidisciplinary team conducted a QI project using the define-measure-analyze-improve-control framework. Root cause analysis identified poor glottic visualization and patient instability as primary drivers of failure. Plan-do-study-act cycles were carried out (April 2023–July 2024), followed by a sustainability phase (August 2024–May 2025). Key interventions included the phased implementation of video laryngoscopy (VL) as the primary intubation device and the standardization of oxygenation during laryngoscopy using nasal high flow. First-attempt success was tracked using statistical process control, and bimonthly VL use was monitored as a process measure. RESULTS A total of 642 intubations were analyzed. By control chart analysis, the first-attempt success rate increased from a baseline of 45% to a sustained process mean of 61% during the intervention and sustainability phases. VL use increased from 0% at baseline to 70% to 90% during the sustainability phase. Success rates improved across all clinician types and locations. Notably, first-attempt success in infants weighing less than 1000 g increased from 38% at baseline to 62% during the intervention phase. CONCLUSION A systematic QI initiative focused on VL and standardized oxygenation improved and sustained neonatal intubation success rates, exceeding the project aim. The maintenance of high-success rates confirms the durability of these safety improvements.
MMDA-13 IMPACT OF BEVACIZUMAB DOSING ON EDEMA RESPONSE IN PATIENTS WITH RADIATION NECROSIS
Schultz, Sydney, Barreto, Jasón, Mead‐Harvey, Carolyn , Sener, Ugur, Sener, Uğur

Mayo Clinic

Neuro-Oncology Advances | August 7, 2026 | Volume: 8 | Issue: Supplement_6 | Pages: No page available

10.1093/noajnl/vdag161.040 Get It

Abstract Background Bevacizumab is a treatment for radiation necrosis; the optimal dosing remains inadequately studied. Methods Retrospective review of adult patients with primary central nervous system (CNS) tumors or brain metastasis treated with bevacizumab for radiation necrosis from 6/29/2021 to 7/31/2024. Primary outcome was to compare edema response with two different bevacizumab doses: 7.5 mg/kg and 10 mg/kg. Edema response was classified according to the following groups: (1) increase of edema, &gt;105% of baseline; (2) constant edema, 75%-105% of baseline; (3) slight decrease of edema, 25%-75% of baseline; (4) large decrease of edema, &lt;25% of baseline. Results 104 patients were evaluated (median age 59 years, 56% male); 53 patients in the 7.5 mg/kg group and 51 patients in the 10 mg/kg group. Tumor type varied significantly across dosing groups (p &lt; 0.001). In the 7.5 mg/kg group, tumor type was primary CNS (n = 23, 43%), lung (n = 14, 26%), breast (n = 8, 15%), melanoma (n = 4, 8%) and other (n = 4, 8%). In the 10 mg/kg group, tumor type was primary CNS (n = 43, 84%), lung (n = 2, 4%), melanoma (n = 2, 4%) and other (n = 4, 8%). Median number of bevacizumab doses administered was 4. There was a statistically significant difference in distribution of edema response across all response levels favoring bevacizumab 10 mg/kg (p = 0.032). When edema response was dichotomized (large decrease vs other), the difference remained statistically significant (p = 0.015). Conclusion Bevacizumab 10 mg/kg was more efficacious in terms of edema response; this result is impacted by the significantly higher incidence of primary CNS tumors in the 10 mg/kg dosing group.
SUPC-01 USE OF THE SELECTIVE PLASMA KALLIKREIN INHIBITOR RZ402 FOR STABILIZATION OF CEREBRAL EDEMA RELATED TO METASTATIC MELANOMA – RESULTS OF A SINGLE PATIENT PROTOCOL
Sener, Ugur, Schultz, Sydney, Galloway, Taylor , Brickley, Vince, Mason, Charles, Huebert, Carey, Headlee, Amy, Burns, Terry, Yan, Elizabeth, Neth, Bryan, Caron, Samantha, Hood, Davelyn , Breit, Jeff, Sener, Uğur , Huebert, Carey, Neth, Bryan J. , Caron, Samantha

Mayo Clinic

Neuro-Oncology Advances | August 7, 2026 | Volume: 8 | Issue: Supplement_6 | Pages: No page available

10.1093/noajnl/vdag161.096 Get It

Abstract Background Peritumoral brain edema (PTBE) is a frequent complication of CNS tumors and radiation therapy (RT). PTBE is primarily treated with corticosteroids, but prolonged use is associated with severe toxicities including myopathy and immunosuppression. Bevacizumab, an alternative treatment, is not recommended in patients with thromboembolic events and intracerebral hemorrhage. Plasma kallikrein is a key driver of tumor-related edema. By targeting this pathogenic enzyme, the orally delivered inhibitor, RZ402, may provide therapeutic value by controlling edema and decreasing corticosteroid use. Methods In this single-patient investigational new drug protocol, we report results from use of RZ402 for treatment of cerebral edema related to metastatic melanoma and RT. Results A 74-year-old man with BRAF-wildtype melanoma had a right frontal and basal ganglia hemorrhagic metastasis not amenable to resection, treated with stereotactic RT (30 Gy, 5 fractions), followed by ipilimumab and nivolumab. MRI obtained 5 months after RT showed increased edema associated with midline shift. After 12 weeks of treatment with high-dose dexamethasone (16 mg daily), edema remained persistent and patient was unable to tolerate dose reduction below 4 mg daily. Course was complicated by a pulmonary embolus prompting initiation of anticoagulation, leading to deferral of bevacizumab. Patient was treated with RZ402, which was tolerated well with no reported toxicities. Dexamethasone was discontinued over 4 weeks. Follow up imaging 6 weeks after RZ402 initiation and off dexamethasone demonstrated stability without rebound edema. Patient did experience adrenal insufficiency characterized by severe fatigue, managed with low-dose prednisone. RZ402 was discontinued after 8 weeks of treatment with patient remaining clinically stable. Conclusion Despite persistent edema after prolonged use of corticosteroids, the selective plasma kallikrein inhibitor RZ402 was associated with radiographic stabilization and discontinuation of dexamethasone for this patient. These findings support prospective evaluation of RZ402 in treatment of symptomatic cerebral edema related to CNS tumors.
Abstract A018: Identifying potential cell-surface targets for therapeutic treatment of DICER1 -related cancers
McNally, Brenya, Mallinger, Paige, Huntsman, David, FCCMG, Zhang, Joyce , Fraire, Claudette R. , Schoettler, Peter J., Schultz, Kris Ann P. , Chen, Kenneth S., Wang, Yemin , Schoettler, P.J.

Mayo Clinic

Cancer Research | July 18, 2026 | Volume: 86 | Issue: 14_Supplement | Pages: A018-A018

10.1158/1538-7445.rareca26-a018 Get It

Abstract INTRODUCTION: Pleuropulmonary blastoma (PPB) and Sertoli-Leydig cell tumor (SLCT) are DICER1-related tumors for which novel therapies are urgently needed. A subset of Wilms tumors are also associated with germline or somatic variants in DICER1. Current therapies include cytotoxic chemotherapy, radiation, and surgery, but there are limited options for patients with recurrent disease. Antibody-Drug Conjugates (ADC) have emerged as promising therapies for several solid tumors. Aberrantly expressed cell surface proteins, including Preferentially Expressed Antigen in Melanoma (PRAME), represent potential targets for immunotherapeutic treatments like CAR-T cell and antibody-based therapies in malignant cancers, including DICER1-associated tumors. METHODS: Individuals diagnosed with PPB, SLCT, and Wilms tumor who enrolled in the International PPB/DICER1 Registry, International OTST Registry, and/or UT Southwestern Pediatric Hematology-Oncology Biorepository were selected for analysis. We analyzed ten PPB samples (four PDX, six primary tumor), four SLCT samples (all primary tumor), and 54 Wilms tumor samples (4 PDX, 50 primary tumor). DICER1 hotspot variants were verified in all 14 PPB and SLCT samples, while none of the Wilms tumor samples we analyzed exhibited DICER1 hotspot variants. Mapped and normalized whole-transcriptome sequencing reads were used to examine expression of 73 targets of antibody- or cell-based therapies that are clinically approved or under clinical investigation on clinicaltrials.gov. Genes with a median expression exceeding 2.5 transcripts per million (TPM) were considered expressed in a given tumor type; this threshold was selected to be permissive in identifying potential targets for further evaluation. RESULTS: Of the 73 genes of interest, 21 targetable cell-surface genes met a median expression threshold of 2.5 TPM in at least one tumor type: 11 genes in PPB, 16 in SLCT, and 14 in Wilms. Seven genes (FN1, PRAME, MCAM, CD248, IL11RA, CD276 (B7-H3), and MRC2) were expressed at this level in all three tumor types. Additional genes were expressed above this level in only two of the tumor types; PDGFRA in PPB and SLCT; GPC2 and TYRO3 in SLCT and Wilms tumor; and CSPG4, ERBB2, FZD10 in PPB and Wilms tumor. Six genes were exclusively expressed in SLCT (AXL, GPNMB, PROM1, KDR, ITGA6, FGFR4), and two were unique to Wilms tumor (GPC1, ULBP3). Of these, PRAME was previously reported as frequently expressed in DICER1-associated tumors; little has been reported about the remaining potential targets. CONCLUSION: PPB, SLCT, and Wilms tumor express several potential immunotherapy targets by RNA-seq. Expression of these potential targets should be investigated by immunostaining in a wider panel of tumors. Further study on the potential for ADCs or CAR-T cell therapies to treat DICER1-related conditions is needed. Citation Format: Brenya McNally, BS, Paige H.R. Mallinger, MS, David Huntsman, MD, FRCPC, FCCMG, Yemin Wang, PhD, Joyce Zhang, PhD, Claudette R. Fraire, PhD, Peter J. Schoettler, MD, Kris Ann P. Schultz, MD, Kenneth S. Chen, MD. Identifying potential cell-surface targets for therapeutic treatment of DICER1-related cancers [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Breaking Barriers in the Fight against Rare Cancers; 2026 Jul 18-20; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(14_Suppl):Abstract nr A018.
Quality Measures Addressing Disparities to Improve Outcomes in Hand Surgery
Schultz, Emily , Richard, Marc J. , Ruch, David S. , Ring, David , Kakar, Sanjeev , Got, Christopher, Akelman, Edward , Blazar, Philip E., Yao, Jeffrey, Sears, Erika D. , Schultz, Emily A , Ring, David , Kakar, Sanjeev , Sears, Erika D , Kamal, Robin N , Shapiro, Lauren M , Snyder, Eli M. , Richard, Marc J., Got, Christopher , Blazar, Philip , Yao, Jeffrey , Ladd, Amy L. , Kamal, Robin N.

Mayo Clinic

HAND | June 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15589447261453556 | PMID 42337843 Get It

Background: There is growing evidence that social determinants of health (SDOH) are associated with disparities in access to care and hand and upper extremity health. Quality measures represent an opportunity to evaluate disparities in access and outcomes that can inform improvement interventions. We performed a systematic review of evidence regarding health disparities within hand surgery and aimed to develop suitable quality measures that are clinically important, feasible, usable, and scientifically acceptable. Methods: We performed a systematic review including common hand surgery terms to identify health disparities in hand surgery related to SDOH. Candidate quality measures were constructed based upon evidence from the systematic review. A consortium of 11 US-based hand and upper extremity surgeons completed a modified RAND/UCLA Delphi Appropriateness process to evaluate the importance, feasibility, usability, and scientific acceptability of the candidate quality measures. Panelists rated each measure on a scale of 1 ( definitely not important/feasible/usable/scientifically acceptable ) to 9 ( definitely important/feasible/usable/scientifically acceptable ) in 2 voting rounds separated by a face-to-face discussion. Agreement among panelists and validity were assessed using predetermined criteria. Results: Fourteen candidate quality measures addressing health disparities were identified based on evidence from the systematic review, including time to surgery and emergency department use after hand surgery based on insurance type, clinical outcomes based on social deprivation, among others. All 14 measures were accepted. Conclusions: Fourteen candidate quality measures were identified and accepted based upon consensus to address health disparities in hand surgery, although future investigation will be needed to evaluate their effectiveness.
Persistence to Botulinum Toxin and Factors Associated With Discontinuation: A Retrospective Cohort Study (P5-14.010)
Wainberg, Michael, Zhang, Jinming, Page, Simon, Bouchard, Jonathan, Mann, Amandeep, BENETEAU, Mathieu, Schultz, Billie, Zhang, Jinming , Page, Simon , Mann, Amandeep, Beneteau, Mathieu , Schultz, Billie A.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216901 Get It